UNION CITY, Calif., Oct. 14 /PRNewswire/ — Questcor
Pharmaceuticals, Inc. (Nasdaq:
QCOR) announced that it is partnering with the Child Neurology
Foundation (CNF) to fund a $30,000 grant to support research into
infantile spasms (IS). Catherine Chu-Shore, MD, of Massachusetts
General Hospital was selected by CNF as the recipient of this
first-ever “Logan Infantile Spasms Research Award.”
“Questcor is committed to CNF and the entire infantile spasms
community,” said Steve Cartt, Executive Vice President and Chief
Business Officer for Questcor. “Further research into this
devastating condition is imperative and we feel strongly about
supporting initiatives that will advance the knowledge and
treatment of infantile spasms.”
Dr. Chu-Shore, whose application was reviewed by 10 of the
nation’s top child neurologists and then selected by the CNF Board
of Directors, said she will focus her research on the “functional
network connectivity” in infantile spasms. IS is a severe,
ultra-rare form of childhood epilepsy that can lead to long-term
cognitive impairment if it is not quickly and successfully treated.
The goal of her research is to identify early metrics of altered
brain connectivity which can serve as biomarkers for
prognostication and treatment stratification for infants with
IS.
“I am very grateful to be the recipient of the Child Neurology
Foundation’s Logan Infantile Spasms Research Award,” said Dr.
Chu-Shore. “This grant provides me with the opportunity to develop
my career as a physician scientist and better understand the
mechanisms of pediatric neurologic disease and their impact on
functional neurodevelopment.”
Dr. Chu-Shore completed her child neurology training at
Massachusetts General Hospital (MGH). Following a year where she
was involved in post-doctoral research, she then completed a
combination epilepsy and neurophysiology fellowship at MGH.
‘/>”/>
